Spots Global Cancer Trial Database for Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Official Title: A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Study ID: NCT03651128
Conditions
Study Description
Brief Summary: This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 109, Birmingham, Alabama, United States
Local Institution - 141, Scottsdale, Arizona, United States
Local Institution - 145, Los Angeles, California, United States
Local Institution - 122, Los Angeles, California, United States
Local Institution - 124, Palo Alto, California, United States
Local Institution - 142, Aurora, Colorado, United States
Local Institution - 108, Jacksonville, Florida, United States
Local Institution - 102, Tampa, Florida, United States
Local Institution - 131, Atlanta, Georgia, United States
Local Institution - 140, Atlanta, Georgia, United States
Local Institution - 139, Chicago, Illinois, United States
Local Institution - 100, Indianapolis, Indiana, United States
Local Institution - 112, Westwood, Kansas, United States
Local Institution - 104, Baltimore, Maryland, United States
Local Institution - 134, Boston, Massachusetts, United States
Local Institution - 123, Boston, Massachusetts, United States
University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Local Institution - 125, Rochester, Minnesota, United States
Local Institution - 114, Saint Louis, Missouri, United States
Local Institution - 138, Hackensack, New Jersey, United States
Local Institution - 119, New York, New York, United States
Local Institution - 115, New York, New York, United States
Local Institution - 135, New York, New York, United States
Local Institution - 113, Durham, North Carolina, United States
Local Institution - 111, Philadelphia, Pennsylvania, United States
Local Institution - 110, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center William M. Cooper Ambulatory Care Pavillion, Pittsburgh, Pennsylvania, United States
Local Institution - 106, Nashville, Tennessee, United States
Local Institution - 118, Dallas, Texas, United States
Local Institution - 103, Dallas, Texas, United States
Local Institution - 132, Houston, Texas, United States
Local Institution - 136, Salt Lake City, Utah, United States
Local Institution - 105, Seattle, Washington, United States
Local Institution - 107, Madison, Wisconsin, United States
Local Institution - 202, Leuven, , Belgium
Local Institution - 302, Calgary, Alberta, Canada
Local Institution - 303, Toronto, Ontario, Canada
Local Institution - 402, Lille Cedex, , France
Local Institution - 403, Nantes, , France
Local Institution - 400, Paris, , France
Local Institution - 401, Toulouse CEDEX 9, , France
Local Institution - 513, Dusseldorf, , Germany
Local Institution - 514, Hamburg, , Germany
Local Institution - 512, Heidelberg, , Germany
Local Institution - 515, Köln, , Germany
Local Institution - 511, Würzburg, , Germany
Local Institution - 611, Bologna, , Italy
Local Institution - 806, Bunkyo-ku, , Japan
Local Institution - 804, Isehara City, Kanagawa, , Japan
Local Institution - 807, Nagoya, , Japan
Local Institution - 805, Shibuya-ku, , Japan
Local Institution - 650, Amsterdam, , Netherlands
Local Institution - 651, Rotterdam, , Netherlands
Local Institution - 700, Oslo, , Norway
Local Institution - 750, Pamplona, , Spain
Local Institution - 751, Salamanca, , Spain
Local Institution - 800, Stockholm, , Sweden
Local Institution - 251, Bern, , Switzerland
Local Institution - 850, Leeds, , United Kingdom
Local Institution - 851, London, , United Kingdom
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
